October 26, 2017 08:52 AM EDT
R&D

Ab­b­Vie boasts a PhI­II sweep for top pso­ri­a­sis con­tender risankizum­ab, but it has lots of com­pe­ti­tion

John Carroll

Editor & Founder

Ab­b­Vie paid Boehringer $595 mil­lion up­front to li­cense rights to risankizum­ab in ear­ly 2016, and this morn­ing the com­pa­ny dis­played a late-stage dataset on pso­ri­a­sis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times